知镜 Cognispect · 医学文献与研究工作台

Safety and efficacy of immune checkpoint inhibitors and hypomethylating agents in treatment-naïve AML and HR-MDS: a systematic review and HR-MDS meta-analysis.

Khoshnegah Z, Rostami M, Khaksari MN, Khazaee-Nasirabadi MH, Arianmanesh F, Jafarnejad F, Khiabani A, Sadatmoosavi A, Zanganeh S, Nezhad FS, Ashoub MH, Jafarzadeh A.
Cancer treatment and research communications · 2026-11-06 · PMID 43002895

文献摘要

Background This systematic review and meta-analysis evaluates the safety and efficacy of immune checkpoint inhibitors (ICIs) combined with hypomethylating agents (HMAs) in patients with treatment-naïve acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS). Methods We systematically searched PubMed, Scopus, and Web of Science from inception to 5 July 2026, and also searched ClinicalTrials.gov and Google Scholar. We included single-arm and controlled studies involving treatment-naïve AML and HR-MDS patients. We performed quantitative meta-analyses of overall response rates (ORR), complete response (CR) rates, and toxicities in HR-MDS studies with sufficient data, using a random-effects model for all outcomes. We assessed risk of bias using the MINORS tool for single-arm studies and the RoB 2 tool for randomized trials. Results The systematic review included 15 articles. Of these, 8 studies contributed treatment-naïve HR-MDS populations and were included in the quantitative meta-analysis; the remaining AML-only and mixed-population studies were synthesized narratively. The pooled ORR was 68 (95% CI: 0.62-0.74). The CR rate was 23 (95% CI: 0.15-0.32). Hematologic toxicities (grade ≥3) included neutropenia (51%), thrombocytopenia (47%), febrile neutropenia (36%), and anemia (33%). Among non-hematologic toxicities, constipation of any grade was most common (52%), while grade ≥3 diarrhea was less frequent (5%). Conclusion ICI-HMA combinations showed descriptive clinical activity in treatment-naïve HR-MDS, with descriptive toxicity rates from single-arm studies, but the certainty of this evidence is low to very low, and randomized trials to date have not demonstrated improved outcomes with the addition of ICIs to HMAs. Quantitative evidence is limited to HR-MDS, highlighting the need for further studies, especially in AML.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。